期刊
HUMAN GENE THERAPY
卷 20, 期 12, 页码 1565-1575出版社
MARY ANN LIEBERT, INC
DOI: 10.1089/hum.2009.163
关键词
-
资金
- American Cancer Society [CRP-08-229-01]
- [P50 CA097190]
- [5P50 CA090440-08S1]
- [RO1 CA77308]
- [RO1 CA101840]
- NATIONAL CANCER INSTITUTE [P50CA097190, R01CA077308, P50CA090440, R01CA101840] Funding Source: NIH RePORTER
The incidence of head and neck cancer continues to increase worldwide, with tobacco exposure and human papillomavirus type 16 infections being the major etiological factors. Current therapeutic options are ineffective in approximately half of the individuals afflicted with this malignancy. Developments in the identification of molecules that sustain head and neck squamous cell carcinoma (HNSCC) growth and survival have made molecular targeting by gene therapy approaches a feasible therapeutic strategy. Although gene therapy was originally designed to correct single gene defects, it has now evolved to encompass all forms of therapeutic interventions involving engineered cells and nucleic acids that modify the overall pattern of gene expression within target tissues. Several preclinical studies and clinical trials have tested the efficacy of targeting specific molecules in patients with HNSCC, using genetic therapy approaches. This review discusses promising preclinical and clinical approaches and new directions for HNSCC gene therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据